



Press release from Emotra AB (publ)

Göteborg, February 12, 2020

## **Emotra's comments on share trade volumes and the share price rise**

**Due to the trading volumes seen in shares in Emotra and the large share price rise in its wake, the Company feels compelled to comment the situation.**

In our latest interim report of October 24, 2019, Emotra stated that even though the "Company's operations are focused on a select few, high-priority activities, it is the Board of Directors' judgement that the Company does not possess sufficient funds to finance the long-term development and a broad, international market introduction of EDOR. The Board is presently discussing how the Company shall secure additional capital in order to ensure continued operations, as well as the financing of a long-term commercial development of EDOR."

The board continues to strongly focus on continued financing of the Company's operations and will inform the market when suitable decisions have been reached. Furthermore, Emotra would like to mention that the Company has published all significant news about its operations. Our latest release concerned an agreement that was signed with the university hospital in Warsaw.

**For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR<sup>®</sup>, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1  
SE-431 83 Mölndal, Sweden, Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)